Overview

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Status:
Terminated

Trial end date:
2017-03-03

Target enrollment:

Participant gender:

Summary

This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and nab-paclitaxel. After three cycles of treatment in the gemcitabine/nab-paclitaxel arm and 6 cycles in the mFOLFIRINOX arm, patients will be restaged with CT scans and if they remain borderline resectable or have improvement of their disease They will then proceed to SBRT followed by surgical resection.

Phase:

Phase 2

Details

Lead Sponsor:

Nathan Bahary, MD
University of Pittsburgh

Treatments:

Albumin-Bound Paclitaxel
Fluorouracil
Gemcitabine
Irinotecan
Oxaliplatin
Paclitaxel